Paulzen, Michael; Haen, Ekkehard; Gründer, Gerhard; Lammertz, Sarah E; Stegmann, Benedikt; Schruers, Koen Rj; Walther, Sebastian; Schoretsanitis, Georgios (2016). Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. Journal of psychopharmacology, 30(8), pp. 803-809. Sage Publications 10.1177/0269881116650390
Full text not available from this repository. (Request a copy)BACKGROUND
Treatment of arterial hypertension in patients with severe mental illnesses often results in polypharmacy, potentially leading to drug-drug interactions. The objective of the study was to analyse the in vivo inhibitory potential of two antihypertensive drugs, amlodipine and metoprolol on CYP2D6 catalysed 9-hydroxylation of risperidone (RIS).
METHODS
A therapeutic drug monitoring database with plasma concentrations of RIS and 9-hydroxyrisperidone (9-OH-RIS) of 1584 patients was analysed. Three groups were considered; a group of patients receiving RIS without a potentially cytochrome influencing co-medication (control group, R0, n=852), a group co-medicated with amlodipine (RA, n=27) and a group, co-medicated with metoprolol (RM, n=41). Plasma concentrations, concentration-to-dose ratios (C/Ds) of RIS, 9-OH-RIS and the active moiety (AM), as well as the metabolic ratios were computed and compared using the Kruskal-Wallis test, the Mann-Whitney U test and the Jonckheere-Terpstra test to determine the means and different patterns of distribution of plasma concentrations as well as the concentration-to-dose ratios.
RESULTS
The median daily dosage of RIS did not differ between the groups (p=0.708). No differences were found in median plasma concentrations of RIS, 9-OH-RIS and AM. However, concentration-to-dose ratios for RIS, 9-OH-RIS and AM were significantly higher in the amlodipine group (p=0.025, p=0.048 and p=0.005). In the metoprolol group, the concentration-to-dose ratio for RIS was significantly higher than in the control group (p=0.017), while the C/D for 9-OH-RIS and AM was not.
CONCLUSIONS AND LIMITATIONS
Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM. Although the interaction did not result in significantly higher plasma levels, changes in C/Ds and their distribution with regard to the median concentrations were observed.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy > Translational Research Center 04 Faculty of Medicine > University Psychiatric Services |
UniBE Contributor: |
Walther, Sebastian, Schoretsanitis, Georgios |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0269-8811 |
Publisher: |
Sage Publications |
Language: |
English |
Submitter: |
Sebastian Walther |
Date Deposited: |
09 Aug 2016 15:41 |
Last Modified: |
05 Dec 2022 14:57 |
Publisher DOI: |
10.1177/0269881116650390 |
PubMed ID: |
27251417 |
Uncontrolled Keywords: |
CYP2D6; Therapeutic drug monitoring; amlodipine; interaction; metoprolol; pharmacokinetics; risperidone |
URI: |
https://boris.unibe.ch/id/eprint/85587 |
Actions (login required)
 |
Edit item |